Drug Trial Radar · NCT07691190
Bioequivalence Study to Compare Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) Versus Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine)
Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Mar 5, 2026
Primary completion
Jun 2, 2026
Study completion Jun 26, 2026
Sponsor
- Lead sponsor
- Humanis Saglık Anonim SirketiIndustry
- Sponsor type
- Industry
- First posted
- Jul 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Single dose oral bioequivalence study of Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine hydrochloride) and Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine) in healthy adult human participants under fasting conditions.
Conditions
- SCHIZOPHRENIA 1 (Disorder)
Interventions
Cariprazine Hard CapsulesDrug
1 capsule of 1.5 mg Cariprazine hydrochloride
Reagila® Hartkapseln (Hard Capsules) (Cariprazine)Drug
1 capsule of 1.5 mg Cariprazine
Primary outcomes
What the sponsor says the trial is designed to measure.
- The area under the plasma concentration versus time curve calculated using the linear trapezoidal rule from the zero time point to the 72 hours (AUC72)Time frame: 72.00 hours
- Maximum measured plasma concentration (Cmax)Time frame: 72.00 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cliantha Research Limited
Gujrāt, Vadodara, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.